Home › Funds › Prosight Management, LP › SNDX

Prosight Management, LP position in SNDX

SYNDAX PHARMACEUTICALS INC · Health Care

Prosight Management, LP reported holding 812,582 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$15.3M, representing 2.96% of its reported portfolio and ranking #13 among its reported holdings. Prosight Management, LP has disclosed SNDX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)812.58K sh
Reported value held$15.28M
Portfolio Weight2.96%
First reportedQ2 2024
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Prosight Management, LP's SNDX position evolved

Prosight Management, LP first disclosed a stake in SNDX in Q2 2024 at 551,544 shares (US$11.3M). The position peaked in Q2 2026 at 1,200,000 shares, worth US$26.2M. Across 10 filings, Prosight Management, LP increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 812,582 shares valued at US$15.3M — a reduction of -387,418 shares quarter over quarter.. Notable position changes include a 77% increase in Q2 2025 (shares rose 64% over the following quarter), a 34% trim in Q4 2025 (shares rose 11% over the following quarter), a 56% increase in Q2 2026 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 551.54K $11.32M New
Q3 2024 554.10K $10.67M Hold
Q4 2024 620.00K $8.20M Add
Q1 2025 609.25K $7.48M Reduce
Q2 2025 1.08M $10.11M Add
Q3 2025 1.00M $15.44M Reduce
Q4 2025 665.00K $13.97M Reduce
Q1 2026 770.00K $17.99M Add
Q2 2026 1.20M $26.23M Add
Q3 2026 812.58K $15.28M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SNDX and 13F data

SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 38 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SNDX

All SNDX fund holders →

FAQ

How long has Prosight Management, LP held SNDX?

Prosight Management, LP has disclosed SNDX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is Prosight Management, LP's current position in SNDX?

As of Q3 2026, Prosight Management, LP holds 812.58K shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $15.28M, representing 2.96% of its reported portfolio and ranking #13.

Has Prosight Management, LP been buying or selling SNDX?

In the latest 13F filing (Q3 2026), Prosight Management, LP reduced its position in SNDX. The position peaked in Q2 2026 at 1.20M shares.

Which other funds hold SNDX?

Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.